Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1710340
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Eton Pharma filed an 8-K on 7/15, updating corporate info. All good.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing details the company's principal executive offices located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois, 60010-7208, and its telephone number is (847) 787-7361. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Eton Pharmaceuticals.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information that suggests significant new risks.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- July 15, 2024 (date) — Filing Date
- 21925 W. Field Parkway, Suite 235, Deer Park, Illinois, 60010-7208 (address) — Principal Executive Offices
- (847) 787-7361 (phone_number) — Registrant's telephone number
- Delaware (state) — State of Incorporation
- December 31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this 8-K filing for Eton Pharmaceuticals?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 15, 2024.
Where are Eton Pharmaceuticals' principal executive offices located?
Eton Pharmaceuticals' principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois, 60010-7208.
What is the telephone number for Eton Pharmaceuticals?
The telephone number for Eton Pharmaceuticals is (847) 787-7361.
In which state is Eton Pharmaceuticals incorporated?
Eton Pharmaceuticals is incorporated in Delaware.
When does Eton Pharmaceuticals' fiscal year end?
Eton Pharmaceuticals' fiscal year ends on December 31.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-07-15 16:16:01
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240708_8k.htm (8-K) — 26KB
- ex_695873.htm (EX-99.1) — 10KB
- 0001437749-24-022736.txt ( ) — 167KB
- eton-20240715.xsd (EX-101.SCH) — 3KB
- eton-20240715_def.xml (EX-101.DEF) — 11KB
- eton-20240715_lab.xml (EX-101.LAB) — 15KB
- eton-20240715_pre.xml (EX-101.PRE) — 11KB
- eton20240708_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On July 15, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing the acceptance of a New Drug Application (NDA) from the U.S. Food and Drug Administration (FDA) for its submission of ET-400, the Company's proprietary patented formulation of hydrocortisone oral solution. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated July 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 15, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4